7.36
-0.19(-2.52%)
Currency In USD
| Previous Close | 7.55 |
| Open | 7.41 |
| Day High | 7.76 |
| Day Low | 7.15 |
| 52-Week High | 11.41 |
| 52-Week Low | 1.73 |
| Volume | 411,652 |
| Average Volume | 610,017 |
| Market Cap | 228.17M |
| PE | -3.96 |
| EPS | -1.86 |
| Moving Average 50 Days | 7.37 |
| Moving Average 200 Days | 5.67 |
| Change | -0.19 |
If you invested $1000 in Sagimet Biosciences Inc. (SGMT) since IPO date, it would be worth $461.44 as of October 18, 2025 at a share price of $7.36. Whereas If you bought $1000 worth of Sagimet Biosciences Inc. (SGMT) shares 1 year ago, it would be worth $1,360.44 as of October 18, 2025 at a share price of $7.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 11:00 AM GMT
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ana
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first half of 2026 SAN MATEO, Calif.